Psychedelics: A New Fountain of Youth?

Psychedelics may help us add healthy years to our lives.

-

LSD and psilocybin have been associated with significant positive changes in clinical measures of depression, anxiety, and psychiatric disorders such as OCD and addiction.1-4 An emerging property of psychedelics, however, is their anti-inflammatory potential. Recent studies have found evidence for the role of the 5-HT2A receptor in the inflammatory response, showing that activation of this receptor modulates a potent anti-inflammatory response in animal models.5,6

More recently, psychedelics have also been found to act on several cell signalling pathways associated with genetic aging, such as the mTOR and BDNF pathways.7 In a study released this year, researchers found that lifetime use of classic psychedelics such as psilocybin and LSD was correlated with significantly greater overall physical health, and lower odds of having a heart condition and/or cancer within the last twelve months.8 But, how robust is this correlation? Could psychedelics be helping us live longer and healthier lives?   

The 5-HT2A Receptor and Inflammation

Low-grade chronic inflammation has been put forth as one of the primary contributors to the development of age-related diseases.9 This is best known as ‘inflammaging’, and it is the result of an excessive immune reaction to specific stressors which worsen over the life course. Psychedelics have been found to elicit strong anti-inflammatory properties through their action on the 5HT2A receptor, and have been posited as promising treatments against inflammatory disorders.10,11

In a landmark study carried out in 2013, researchers showed that selective activation of the serotonin 5-HT2A receptor is able to block the effects of tumour necrosis factor-alpha (TNF-α), which plays a key role in inflammation.12 Charles Nichols, a proponent of this theory, has suggested that psychedelics may in fact be a powerful and effective treatment for age-related diseases such as atherosclerosis and inflammatory bowel disease. His company, Eleusis, intends to carry out preclinical and clinical trials in the coming years on the anti-inflammatory potential of psychedelics, which they are seeking to develop outside of their perceptual and consciousness-altering properties.13

The ‘Psilocybin-Telomere Hypothesis’

Telomeres, the small ‘caps’ at the end of chromosomes, have been implicated as key markers of genetic aging since the 1980s.14 Telomere shortening caused by the aging process has been linked to premature cell senescence, genetic instability, and an impaired DNA damage response, leading to a global decline in function as we get older.15 Interestingly, telomeres have been found to function as ‘psychobiomarkers,’ that is, they are in part regulated by psychological factors such as depression and anxiety.

A recent meta-analysis of 38 studies investigating the relationship between telomere length and depression found a significant inverse correlation between these two factors.16 In 2020, Christopher B. Germann proposed that psilocybin could be having a direct positive impact on leukocyte telomere length, particularly in the brain. His theory, which he coined the ‘psilocybin-telomere hypothesis’ was based on deductive logic: if depression shortens telomeres and psilocybin reduces depression, then psilocybin must have an effect on telomere length and therefore genetic aging.17

mTOR, BDNF, and Synaptic Plasticity

Recently, serotonergic psychedelics have also been found to elicit profound changes in neuroplasticity through their action on the mTOR (mammalian target of rapamycin) and BDNF (brain-derived neurotrophic factor) cellular pathways.18-20 Both mTOR and BDNF  have been widely associated with genetic aging, in particular age-related neurodegeneration.21,22 In four separate peer-reviewed studies, the anti-depressant effects of ketamine, ayahuasca, LSD, and psilocybin were strongly associated with their effects on these signalling pathways.23-26

While the mechanism of action of psychedelics on these aging-related pathways is not yet fully understood, it has been thought to involve the BDNF-enhanced delivery of AMPA to the synapse.27 Researchers such as Robin Carhart-Harris have suggested that this action could explain the enhancement of neural plasticity elicited by psychedelics, as well as the phenomenological feelings of “resetting” following a psychedelic experience.28

Conclusion

Through their action on inflammatory pathways as well as those classically associated with genetic aging such as telomere length and the activation of the mTOR and BDNF pathways, serotonergic psychedelics seem to do more than just change consciousness. Evidence is mounting for the possible use of psychedelics in slowing down genetic aging and cognitive decline over the life course. It is still too early to say whether anti-aging therapies are a possible future use of psychedelics, but the science seems to be pointing in that direction.

Comments

3 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
Clara Chávez
2 months ago

Very interesting I love it

Jean-Paul
2 months ago

What about the use of DMT, cannot leave it out as a healing medicine as well.

Helena
1 month ago

I wouldn’t push the telomere hypothesis so much… there’s no evidence for it at all yet, it’s really just a pipe dream idea for a potential future research project which may or may not find anything interesting. Another important point is that increased neuroplasticity has mainly been researched in the cortex, but the main target to fight neurodegeneration would be the hippocampus – which studies suggest may not benefit from psychedelics much at all! We should be patient and not get ahead of the science if we want people outside the field to take psychedelics seriously. I get the high… Read more »

    References
  1. Daniel J, Haberman M. Clinical potential of psilocybin as a treatment for mental health conditions. Ment Health Clin. 2017;7(1):24-28. doi:10.9740/mhc.2017.01.024
  2. Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects. Journal of Psychopharmacology. 2015;29(1):57-68. doi:10.1177/026988111455524
  3. Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735-1740. doi:10.4088/jcp.v67n1110
  4. Nielson EM, May DG, Forceheims AA. The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions. Front Pharmacol.2018;9. doi:10.3389/fphar.2018.00132
  5. Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents. Int Rev Psychiatry. 2018;30(4):363-375. doi:10.1080/09540261.2018.1481827.
  6. Nichols DE, Johnson MW, Nichols CD. Psychedelics as Medicines: An Emerging New Paradigm. Clin Pharmacol Ther. 2017;101(2):209-219. doi:10.1002/cpt.557.
  7. Inserra A, De Gregorio D, Gobbi G, Nader M. Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms. Pharmacological reviews. 2021;73(1):202-277. doi:10.1124/pharmrev.120.000056
  8. Simonsson O, Sexton JD, Hendricks PS. Associations between lifetime classic psychedelic use and markers of physical health. J Psychopharmacol.2021;35(4):447-452. doi:10.1177/0269881121996863
  9. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576-590. doi:10.1038/s41574-018-0059-4
  10. Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents. Int Rev Psychiatry. 2018;30(4):363-375. doi:10.1080/09540261.2018.1481827
  11. Szabo A, Kovacs A, Frecska E, Rajnavolgyi E. Psychedelic N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethytriptamine Modulate Innate and Adaptive Inflammatory Responses through the Sigma-1 Receptor of Human Monocyte-Derived Dendritic Cells. PLoS One. 2014;9(8). doi:10.1371/journal.pone.0106533
  12. Nau F Jr, Yu B, Martin D, Nichols CD. Serotonin 5-HT2A receptor activation blocks TNF-α mediated inflammation in vivo. PLoS One. 2013;8(10):e75426. doi:10.1371/journal.pone.0075426
  13. Pipeline: Developing a broad and differentiated portfolio of drug candidates to address unmet needs within and beyond psychiatry. Eleusis. Accessed May 25, 2021. https://www.eleusisltd.com/pipeline/
  14. Cooke HJ, Smith BA. Variability at the telomeres of the human X/Y pseudoautosomal region. Cold Spring Harb Symp Quant Biol. 1986;51(1):213-219. doi:10.1101/sqb.1986.051.01.026
  15. Harley CB, Vaziri H, Counter CM, Allsopp RC. The telomere hypothesis of cellular aging. Experimental Gerontology. 1992;27:375–382. doi:10.1016/0531-5565(92)90068-b
  16. Ridout KK, Ridout SJ, Price LH, Sen S, Tyrka AR. Depression and telomere length: A meta-analysis. J Affect Disord. 2016;191:237-247. doi:10.1016/j.jad.2015.11.052
  17. Germann CB. The Psilocybin-Telomere Hypothesis: An empirically falsifiable prediction concerning the beneficial neuropsychopharmacological effects of psilocybin on genetic aging. Medical Hypotheses. 2019;134:109406. doi:10.1016/j.mehy.2019.109406
  18. Ly C, Greb AC, Cameron LP et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170–3182. doi:10.1016/j.celrep.2018.05.022
  19. Dakic V, Minardi Nascimiento J, Costa Sartore R, et al. Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT. Scientific Reports. 2017;7:12863. doi:10.1038/s41598-017-12779-5
  20. Mazucanti CH, Cabral-Costa JV, Vasconcelos AR, Andreotti DZ, Scavone C, Kawamoto EM. Longevity Pathways (mTOR, SIRT, Insulin/IGF-1) as Key Modulatory Targets on Aging and Neurodegeneration. Curr Top Med Chem. 2015;15(21):2116-2138. doi:10.2174/1568026615666150610125715
  21. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature. 2013;493(7432):338-345. doi:10.1038/nature11861
  22. Li N, Lee B, Jian-Liu R, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959–964. doi:10.1126/science.1190287
  23. Berman RM, Cappiello A, Anand A et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–354. doi:10.1016/s0006-3223(99)00230-9
  24. de Almeida RN, de Menezes Galvão AC, da Silva FS et al. Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial. Frontiers in Psychology. 2019;10:1234. doi:10.3389/fpsyg.2019.01234
  25. Hutten NRPW, Mason NL, Dolder PC et al. Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers. ACS Pharmacol Transl Sci. 2020;4(2):461-466. doi:10.1021/acsptsci.0c00099
  26. Jefsen O, Elfving B, Wegener G, and Muller HK. Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin. J Psychopharmacol. 2020;35(4):483-493. doi:10.1177/0269881120959614
  27. Caldeira MV, Melo CV, Pereira DB et al. Brain-derived neurotrophic factor regulates the expression and synaptic delivery of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunits in hippocampal neurons. J Biol Chem. 2007;282:12619–12628. doi:10.1074/jbc.M700607200
  28. Carhart-Harris RL, Roseman L, Bolstridge M et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific reports. 2017;7(13187). doi:10.1038/s41598-017-13282-7